

Industry Standing Group (ISG) meeting, 28 June 2024


Ralf Herold and Pierpaolo Moscariello Regulatory Science and Academia Workstream Task Force Regulatory Science & Innovation












EUROPEAN MEDICINES AGENCY

EMA advancing regulatory science research





September 2023
 Proposal to
set up a ISG
focus group
on
regulatory
science
research
translation

Proposal to set up a FG



19 December 2023 EMA/423751/2023

Highlights - 6th Industry Standing Group (ISG) meeting

21st September 2023 – chaired by Marie-Hélène Pinheiro

7. EMA Regulatory Science and use of public private partnerships' results to address Regulatory Science Needs

EMA provided an overview of the work being done by EMA on identifying the progress and updating the Regulatory science research needs (RSRN), which were published end 2021 and are linked to the Strategic goal 5 in the <u>EMA Regulatory Science Strategy to 2025</u>. The RSRN includes a lifecycle approach where the goal is to close regulatory gaps through translation of results, for example by updating the regulatory standards and guidelines, informing scientific advice to developers and improving medicines development and assessment, and additional ways to translate to achieve visible impact that should be explored and established. A public consultation is considered for the draft updated RSRN.


EFPIA presented a summary of their mapping analysis of EMA's published RSRN against completed or ongoing projects under the IMI/IHI Partnerships, highlighting areas of potential high public health impact and the need for accelerating getting to regulatory acceptance. Industry proposed to set up a focus group aiming to reflect on mechanisms for efficiently translating results coming from such publicprivate undertakings, on optimising how to establish regulatory acceptance, and on creating impact through use in research and regulatory practice.

Actions arising:

 EMA to further reflect on the proposal to set up a focus group to continue the dialogue with relevant Industry stakeholders.

Link to EMA presentation.





The objective of this group is to **develop recommendations, priorities and approaches** for enhancing the translation of regulatory science research outputs into practical application in research and development and in improved regulatory standards and practices.

Translation includes advancing the regulatory framework for the development, evaluation and use of medicines and drug development tools, as well as maximising the uptake and application of research outputs by relevant stakeholders.

In addition to nominated members from industry organisations, a multistakeholder approach will be used by involving relevant academic stakeholders, researchers, funders, and the European Commission.

The following outcomes are expected:

- **Define relevant actors** for initiating and progressing the translation of regulatory science research outputs.
- **Describe relevant existing and any newly required translation approaches**, including criteria, governance, milestones and deliverables (e.g., training and competency building, stakeholders needed, type of regulatory endorsement needed, requirements for raising awareness and for availability of tools).
- Define key elements to be considered when establishment and running of private-public partnerships to ensure early embedding of relevant translation approaches to obtain regulatory support and practical application.
- Develop reflections on what is needed to accelerate the process of translation of research outputs, and to maintain acceleration and efficiency of translation of regulatory science research outputs for the benefit of patients and public health.



	Consortia/RSRN			Drafting of recommendations and		
	- Objectives - Expected impact	Case studies (1 meeting/month; 1 case/meeting) Presentation of research outcomes (data and results) Define category of research outcomes Define strength/maturity of research outcomes		 principles by: Designated members from industry EMA members Academic members Feedback and comments from DG-RTD 		
 Selection of case studies by: Designated members from industry EMA members 		 → problem identified → new datasets → solutions/recommendations - Discuss gaps of research translation 	Principles Possible translational pathways Elements for highest possible impact and translation 			
		 Meetings prepared by: Designated members from industry Academic members DG-RTD members EMA members 	ide - R acc	Key actors involved in the relevant lentified translational pathways Reflections on needed elements for cceleration of the translation process Recommendations for key stakeholders		

September	January	February-April	May
2023	2024	2024	2024
 Proposal to 	 Nomination 	 1 meeting/month to 	 Meeting to
set up a ISG	of 2	discuss case studies	discuss
focus group	members	and identify challenges	collected
on	for trade	for translation	challenges
regulatory	association		and reflect
science			on potential
research	 Kick-off 		principles to
translation	meeting to		foster
	agree on		optimal
	objective		translation
	and working		of research
	method		outputs

Overview on cases agreed by FG for discussion



Clusters

1. Biomarkers

- 2. Clinical research methodologies
- 3. 3Rs-related methods

Examples of gaps and steps for further translation

- Dissemination and adoption of research outputs
- Tracking of adoption and implementation of developed models
- Regulatory interactions and flexibility of current system
- Protocols optimization
- Data sharing and accessibility
- Training of academia
- Beyond qualification procedure
- Future fundings
- Priorities of academia and Industry
- Resources availability and sharing
- Fragmentation of regulatory pathway



September	January	February-April	May	July-November	December	Q1
2023	2024	2024	2024	2024	2024	2025
 Proposal to set up a ISG focus group on regulatory science research translation 	 Nomination of 2 members for trade association Kick-off meeting to agree on objective and working method 	 1 meeting/month to discuss case studies and identify challenges for translation 	 Meeting to discuss collected challenges and reflect on potential principles to foster optimal translation of research outputs 	 Discuss case studies, identify challenges and reflect on principles to optimize translation of research outputs 1 x Biomarkers 1 x Clinical research methodologies 	 Meeting to discuss collected challenges and reflect on potential principles to foster optimal translation of research outputs 	 Finalize inputs on principles and recommend ations Report FG outcomes

- Focus group had instructive discussions on factors influencing translation of outputs
- Outputs of diverse cases projects led to identify broad set of actors and activities
- Some more cases sought to be discussed, while drafting recommendations
- Report and recommendations anticipated to cover, e.g.,
 - Types of gaps to be filled for adopting and translating research outputs
 - Opportunities for accelerating translation through multiple stakeholders' coordinated action
 - Principles and recommendations to engage with consortia on translation



Any questions?

Further information

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands **Telephone** +31 (0)88 781 6000 **Send us a question** Go to www.ema.europa.eu/contact



Classified as internal/staff & contractors by the European Medicines Agency